Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224490 · ClinicalTrials.gov registry record · Phase 1
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
A Phase 1 study of SARS-CoV-2 and Reproductive Disorder, sponsored by Stephanie B. Seminara, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07224490 is a Phase 1 study of SARS-CoV-2 and Reproductive Disorder that is actively recruiting participants, run by Stephanie B. Seminara, MD. The registered enrollment target is 40 participants, below the 3,768-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07224490, a Phase 1 study of SARS-CoV-2 and Reproductive Disorder, is actively recruiting participants, sponsored by Stephanie B. Seminara, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin. This study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characterization of endogenous LH secretion before and after kisspeptin administration. This frequency of blood sampling is required to define the features of LH pulses.
Conditions Studied
Interventions
- DRUG Kisspeptin 112-121
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224490
The ClinicalTrials.gov registry entry for NCT07224490 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,768-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (99% lower). The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which Kisspeptin 112-121 is the first listed.
NCT07224490 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07224490 about?
NCT07224490 is a clinical study titled "Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease". The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin. This study will utilize the technique of freq...
What is the current status of trial NCT07224490?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-03. Estimated completion is 2030-05.
What conditions does trial NCT07224490 study?
This clinical trial studies the following conditions: SARS-CoV-2, Reproductive Disorder, Neurodegeneration.
What interventions are being tested in trial NCT07224490?
The interventions under investigation include: Kisspeptin 112-121 (DRUG).
Who is sponsoring clinical trial NCT07224490?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224490 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
COMPLETED · Phase 1
-
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
COMPLETED · Phase 1
-
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COMPLETED · Phase 1
-
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
COMPLETED · Phase 1
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.